CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) Director Richard Young acquired 16,378 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $1.65 per share, for a total transaction of $27,023.70. Following the acquisition, the director owned 186,388 shares in the company, valued at approximately $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
CAMP4 Therapeutics Trading Down 3.6%
CAMP4 Therapeutics stock traded down $0.15 during midday trading on Wednesday, reaching $4.01. 86,050 shares of the stock traded hands, compared to its average volume of 176,472. The firm has a fifty day moving average price of $4.02 and a two-hundred day moving average price of $4.31. The firm has a market cap of $208.24 million, a price-to-earnings ratio of -1.70 and a beta of 0.22. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.32 and a fifty-two week high of $7.75.
CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last posted its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The firm had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Analysts anticipate that CAMP4 Therapeutics Corporation will post -0.84 earnings per share for the current year.
Hedge Funds Weigh In On CAMP4 Therapeutics
Analyst Upgrades and Downgrades
Several brokerages have weighed in on CAMP. Zacks Research downgraded CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. raised CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. Rodman & Renshaw assumed coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Weiss Ratings lowered shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.36.
Check Out Our Latest Analysis on CAMP
About CAMP4 Therapeutics
CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.
Featured Articles
- Five stocks we like better than CAMP4 Therapeutics
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
